ロード中...
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination
Histone deacetylase (HDAC) inhibitors represent an encouraging class of antitumor drugs. HDAC inhibitors induce a series of molecular and biological responses and minimal toxicity to normal cells. Citarinostat (Acy-241) is a second generation, orally administered, HDAC6-selective inhibitor. Momeloti...
保存先:
| 出版年: | Apoptosis |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer US
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7244621/ https://ncbi.nlm.nih.gov/pubmed/32394008 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10495-020-01607-3 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|